Connect with us

Featured

Organicell Regenerative Medicine Inc (OTCMKTS: OCEL) Heating Up as Biotech Prepares for its Phase I/II Randomized, Double Blinded, Placebo Trial for Zofin

Published

on

Organicell Regenerative Medicine Inc (OTCMKTS: OCEL) is making an explosive move up the charts after the Company announced the Mayo Clinic will be the site for clinical trials on Chronic Obstructive Pulmonary Disease (COPD). Mayo Clinic in Phoenix, Arizona will be the clinical trial site for Organicell’s Phase I/II Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Zofin for the Treatment of Chronic Obstructive Pulmonary Disease (COPD). 

Earlier this year the Company closed on an additional $1 million private stock purchase at $0.04 per share and secured a $10 Million Equity Line of Credit with Tysadco Partners, LLC. This capital raise brings the total amount of new funding deals to $16.5 Million. The Company has also been busy expanding its BOD and management team recently recruiting Ryan Likes as new Chief Operating Officer, David Aciego as Chief Information Officer, and Jacqueline (Jackie) Domenechas Director of Finance. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Organicell Regenerative Medicine Inc (OTCMKTS: OCEL) is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and to provide other related services. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Organicell RAAM Products and related services are principally used in the health care industry administered through doctors and clinics. 

Since May 2019, Organicell has operated a placental tissue bank processing laboratory in Miami, Florida for the purpose of performing research and development and the manufacturing and processing of the anti-aging and cellular therapy derived products that we sell and distribute to our customers. 

The Company’s leading product, Zofin™ (also known as OrganicellTM Flow), is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines, chemokines, and 102 unique microRNAs as well as other exosomes/nanoparticles derived from perinatal tissues. 

To date, the Company has obtained certain Investigation New Drug (“IND”), and eighteen emergency IND (“eIND”) approvals from the FDA, including applicable Institutional Review Board (“IRB”) approvals which authorized the Company to commence clinical trials or treatments in connection with the use of Zofin™ and related treatment protocols. The Company is pursuing efforts to complete its already approved clinical studies (see below) as well as obtaining approval to commence additional studies for other specific indications it has identified that the use of its products will provide more favorable and desired health related benefits for patients seeking alternative treatment options than are currently available. The ability of the Company to succeed in these efforts is subject to among other things, the Company having sufficient available working capital to fund the substantial costs of completing clinical trials, which the Company currently does not have, and ultimately, obtaining approval from the FDA. 

To Find out the inside Scoop on OCEL Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

OCEL

On November 15 OCEL announced the Mayo Clinic will be the site for clinical trials on Chronic Obstructive Pulmonary Disease (COPD). Mayo Clinic in Phoenix, Arizona will be the clinical trial site for Organicell’s Phase I/II Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Zofin for the Treatment of Chronic Obstructive Pulmonary Disease (COPD). 

Organicell completed the site activation and is ready to begin enrollments. Organicell aims to demonstrate the safety of Organicell’s lead extracellular vesicle biologic, Zofin, while concurrently investigating the drug’s potential long-term benefits for improved pulmonary function and quality of life measures in chronically ill COPD patients. Extracellular vesicle and exosome-based drugs, like Zofin, are becoming increasingly popular due to the number of anti-inflammatory and immune-modulatory effects. In chronic illnesses where inflammation is high, such as COPD, extracellular vesicles and exosomes offer an innovative solution for patients with unmet medical needs. 

COPD including emphysema and chronic bronchitis – a common airway disease that affects approximately 10% of individuals over 45 years of age, is a concern in patients who are infected with the Sars-Cov-2 viruses causing covid-19 disease. It is well known that COPD patients are prone to viral exacerbations and current evidence shows that COPD patients have increased pulmonary expression of ACE2, the SARS-CoV-2 receptor, providing a mechanism by which COPD patients may be more susceptible to COVID-19. COPD patients also demonstrate features of endothelial cell dysfunction and increased coagulopathy, which may predispose to increased risk of worse outcomes from COVID-19. 

Organicell’s Chief Medical Officer, Dr. George Shapiro said, “The association between COPD patients and Covid-19 is now clear. Based on the results I have seen in the numerous Emergency Investigative New Drug treatments we’ve conducted; this COPD trial was a natural progression of Organicell’s science. COPD patients who have Covid-19 are two and half times more likely to experience ICU admissions, invasive mechanical ventilation, or death. Clinical outcomes including requirement for mechanical ventilation and mortality appear to be worse in COPD patients resulting in a three-fold greater risk of mortality. If people with this underlying condition do get COVID-19, they are at high risk for complications and poorer outcomes. There is likely another round of COVID bound to hit this flu season. The timing of this trial couldn’t be more relevant to those suffering with COPD.” 

For More on OCEL Subscribe Right Now!

Currently trading at $40 million market valuation OCEL OS is 1,479,126,390 with 535,327,372 shares in the public float. While the Company does carry $7 million in liabilities on the books, they have raised $16.5 million in new funding deals. OCEL has fast growing revenues recently reporting$1,713,214 in revenues for the 3 months ended July 31, 2021 up from $1,367,895 for the same period last year. Right now, is a very exciting time for OCEL as the Company begins its Phase I/II Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Zofin for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) at the Mayo Clinic in Phoenix, Arizona. OCEL has a long history of explosive moves skyrocketing to over $0.50 in 2020 and to over $0.60 in 2021. We will be updating on OCEL when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with OCEL.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in OCEL either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

HUMBL, Inc. (OTCMKTS: HMBL) Stock Price is on the Rise After a Series of Developments and New Product Releases

Published

on

HUMBL, Inc. (OTCMKTS: HMBL) is a company whose stock price has a tendency to be either very stable or make massive surges and drops. The company’s stock saw a massive surge in late 2020, which continued throughout January 2021, as well. After reaching its peak near $7 in early February 2021, the price started spiraling down.

The rest of 2021 was marked by price drops, which also continued into 2022. The situation finally took a positive turn in 2023, when the price reached its bottom on February 6th, sinking to $0.0073. After that, however, it suddenly spiked up, reaching $0.0184 on February 8th.

Unfortunately, the sudden spike was followed by a sharp drop, which started immediately after the price peaked. Several support levels that the price hit along the way slightly softened the fall, such as the ones at $0.013, $0.012, and $0.010. However, the HMBL price kept going further and further down until it dropped to levels that were not seen since November 2020.

To Find out the inside Scoop on HMBL, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The price reached its two-year low on March 16th by sinking to $0.0058. Then, suddenly, it started heading up again with a new 24% surge which took it back up to $0.009. At the time of writing, the price has corrected to $0.0081.

screenshot-www.tradingview.com-2023.03.22-11_25_09

HUMBL, Inc. (OTCMKTS: HMBL) Has been busy in 2023 so far, which is why its price has started making attempts to recover after two years of constantly spiraling down. Granted, its attempts to go up were cut short, but the company has made some major moves. One possible reason why HUMBL saw its early February spike is an announcement of a new marketing program with Emerling-Gase Motorsports and Joey Gase. The new sponsorship deal was a big move for the company, as it will be advertised during the 2023 NASCAR XFINITY race at Daytona International Speedway. However, that was not the end of it. Only two days later, new reports emerged stating that HUMBL managed to reduce its debt by $10.8 million. In addition, it announced a strategic move to simplify operations and focus on core technology via a subsidiary spin-off of Tickeri.

Three days after that, the company also launched its HUMBL mobile wallet, and a month later, HUMBL Chat audio rooms also went live. This was the company’s attempt to take the next step in delving deeper in the Web3 revolution. HUMBL previously launched a variety of Web3 products, such as HUMBL Authentics, HUMBL Chat, the mentioned HUMBL Wallet, HUMBL Tickets, HUMBL Social, HUMBL Search Engine, and HUMBL Marketplace.

For more on HMBL Subscribe Right Now!

On March 16th, reports also revealed the rollout of HUMBL’s new digital P2P and merchant payments system, launched across the Web3 platform, which allows users to make payments to verified peers using Ethereum, Polygon, or USD Coin. This is likely what caused the new price increase that HMBL has seen over the last few days, and while it was fairly short-lived, it still represented an opportunity for investors and a positive move for the company.

HUMBL, Inc. (OTCMKTS: HMBL) is a Web3 platform that features consumer and commercial divisions. The firm intends to integrate core product lines across its numerous products, including HUMBL Wallet, Search Engine, Social Media, Marketplace, Tickets, and Authentics. The company also deals in NFTs, and it even has its own metaverse. It also acts as a financial data transactions firm, with its platform connecting consumers and merchants in the digital economy. The company was quick to switch to new technologies after realizing their potential in its sector, particularly when it comes to various crypto and blockchain products mentioned above. These days, it offers its products and services to customers around the world.

The company’s CEO, Brian Foote, stated:

HUMBL is the first web3 platform in the world to deliver an integrated digital wallet, search engine, digital payments and a verified social media platform in one place. We believe that the global markets are going to move from traditional banking and middlemen services, to more inclusive digital wallets. Having verified users and merchants on HUMBL, is a natural way for customers around the world to find and send reliable peer payments and transactions between one another without a bank or middleman for verification, sending and settlement.”

HUMBL, Inc. (OTCMKTS: HMBL) is a company that has developed a wide range of Web3 services that have not yet caught the attention of the public. However, as crypto and blockchain adoption continues to expand and progress, the company’s time will come. After mass adoption hits, HUMBL will be ready to offer its products and possibly become one of the leaders in offering Web3 services that are simple to use for Web2 users. With that said, the firm might simply be ahead of the times, which would explain why its shares are currently so low. On the other hand, this represents a great opportunity for long-term investors who might conclude that HUMBL has great potential for the future. We will be updating HMBL when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with HMBL.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Pexels from Pixabay

Continue Reading

Featured

Creatd, Inc. (OTCMKTS: CRTD) Stock Price Continues to Deteriorate as the Legal Battle with The Lind Partners, LLC Continues

Published

on

Creatd, Inc. (OTCMKTS: CRTD) share value continues to drop after a brief recovery in mid-March. The firm’s stock is still not at the lowest point it has ever been, but it is not too far off at this point. The lowest that the shares have gone was $0.0457, which is the point they reached on October 11th, 2022. After that, in the final months of the previous year, the stock price shot up, reaching $1.6941 per share on November 18th.

The last time when the shares reached this height was in February 2022. However, back then, the price was rapidly spiraling down from a much higher point. Unfortunately for the company and its investors, after reaching $1.6941 in November, the share price crashed in a sharp correction, sinking to $0.50 by the end of November.

CRTD found a strong support at this level, which allowed it to bounce back up to $0.90, which is where the company encountered a strong resistance. It kept bouncing back and forth between these two levels throughout December 2022 and January 2023. However, as time passed, the fluctuations were becoming smaller, as the price seemingly started achieving greater stability. Looking back now, however, it becomes clear that the volatility may have decreased, but the overall trend became bearish somewhere in mid-January.

To Find out the inside Scoop on CRTD, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

CRTD price was dropping again, and in the second half of February, it broke the support level at $0.50, sinking to $0.16 by February 27th. After briefly recovering in early March, the price went back up to $0.3, encountering a resistance here, as well, which pushed it back down to $0.1156 this time, which was on March 14th. In the last 48 hours, the price managed to recover a bit once more, sitting at $0.15 at the time of writing.

Creatd, Inc. (OTCMKTS CRTD) stock price continues to deteriorate as the legal battle with The Lind Partners, LLC continues

Creatd, Inc. (OTCMKTS: CRTD) stock has seen a rough performance over the last year, with only a brief period of recovery in November 2022. Other than that, the last 12 months were marked by nothing but price crashes triggered by various events that followed the company. In recent months — specifically in December — the company announced an upcoming merge with Global Tech Industries, albeit without disclosing the terms of the deal. After that, reports said that Global Tech Industries had decided to bid $100 million in stock in order to acquire Creatd. Creatd even halted any discussions with other potential acquirers for 30 days as part of the LOI. At the time, its CEO and Chairman, Jeremy Frommer, said:

There are two elements to this merger, fundamental and technical. The opportunity to advance the Creatd business model and scale revenues coupled with the unique technical position we find our two public companies in, is a momentous opportunity. At the time of closing of any proposed transaction, GTII share delivery to Creatd shareholders will only occur in instances of registered ownership with the transfer agent or DTC.

For a time, everything was going well for the company until February 24th, when reports emerged that Creatd had terminated the proposed acquisition discussions with Global Tech. This was what triggered the stock crash, as many were disappointed that the deal did not succeed.

Around that time, the company was also struggling with a potential illegal naked short selling, and it launched CEOBLOC to try and fight it. One positive development at the time was the fact that CRTD became available on Upstream, which marked the third issuer to dual-list their shares on Upstream’s blockchain-powered market.

https://twitter.com/UpstreamXchange/status/1625520006770618368

However, the stock was hit with another blow a week ago when Creatd released an update regarding its legal dispute with The Lind Partners, LLC, and the company’s affiliates. The dispute concerns a convertible promissory note that amounts to $900,000.

For more on CRTD Subscribe Right Now!

According to Lind, Creatd breached certain representations and warranties in regard to the note. Lind demanded immediate repayment of the full amount, but Creatd instead decided to offer a number of alternatives. Lind refused to negotiate and Creatd filed a motion to dismiss. The company’s CEO said:

At this early stage, we are strictly trying to analyze data. There is more than enough evidence that there has been unusual trading in CRTD and it demands further investigation. To that end, we have asked legal counsel to look into filing multiple requests of trading records from market makers in CRTD stock. When and if the Company enters the discovery period in The Lind Partners, LLC case, any trading records related to The Lind Partners, LLC that were done with external broker dealers will also be analyzed.

Creatd, Inc. (OTCMKTS: CRTD) is a holding company that offers new economic opportunities to creators using partnerships and technology. The company’s goal is to empower creators and brands, and it claims that each of its companies shares a common mission — to create technologies and develop partnerships that would allow it to unlock new opportunities useful to entrepreneurs, brands, and creators, allowing them to also grow creatively, sustainably, as well as profitably.

For the moment, it appears that the situation is not the best for the company. It is in the middle of legal proceedings, its merger has failed, and its stock is one bad day away from reaching its all-time low. The chart above shows that CRTD is willing to grow and ready to jump on any opportunity, so the company still has a chance. Any piece of good news would likely send its stock to the path of recovery, which is why it is still worth keeping an eye on future developments. We will be updating on CRTD when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CRTD.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Sang Hyun Cho from Pixabay

Continue Reading

Emerging Markets

Is today’s surge in MMTec Inc (NASDAQ: MTC) justified ?

Published

on

MMTec, Inc. (NASDAQ: MTC) ended the day at $2.0700 with a gain of $0.5800 (+38.93%). The stock prices fluctuated between $1.4000 - $2.5299, with more than 2.98M shares exchanging hands.

MMTec, Inc. (NASDAQ: MTC) ended the day at $2.0700 with a gain of $0.5800 (+38.93%). The stock prices fluctuated between $1.4000 – $2.5299, with more than 2.98M shares exchanging hands.

So why did MTC surge today ?

The failure of Silicon Valley Bank led to a sell-off in equities and a shift to safe-haven assets, such as US Treasuries and gold. Markets have calmed down somewhat, and the worst of the equity sell-off seems to be over. However, the market anticipates that the markets will be somewhat uneasy until a better understanding of inflation is reached and what the Federal Reserve will do next week.

To Find out the inside Scoop on MTC, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Despite most investors currently avoiding the banking sector, Wall Street sees potential opportunities, particularly in regional banks. The chaos in the market has created opportunities in the industry and several banking stocks are being punished just for being a banking stock. The collapse of Silicon Valley Bank was due to its specialisation in venture-capital financing, which made it vulnerable to the higher interest rate regime of the past 12 months.

For more on MTC Subscribe Right Now!

Therfore, today’s gains in MTC seems to be more a sympathy bounce considering the overall banking sector. Earlier in March, MMTEC, Inc. (Nasdaq: MTC) declared that it will relocate its operations from Beijing to the Hong Kong Special Administrative Region, effective March 6, 2023. The Company’s subsidiary, MM Future Technology Limited, which is a Hong Kong incorporated limited company, will assume all operations previously conducted by its subsidiary, Gujia (Beijing) Technology Co., Ltd. However, Gujia will continue to carry out specific technical research and development functions. Further, the Company, through its subsidiary HC Securities (HK) Limited, and other entities, will continue to invest its human resources in asset management and securities underwriting, and other related businesses, aiming to attract global funds to invest in the Chinese market and support China’s economic growth. The Company’s new operations headquarters is located at Room 2302, 23rd Floor, FWD Financial Center, 308 Des Voeux Road Central, Sheung Wan, Hong Kong.

We will be updating on MTC when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with MTC.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have no position in MTC and have not been compensated for this article.

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.